RESPONSE BIOMEDICAL AND SHIONOGI FINALIZE COMMERCIALIZATION AGREEMENT

A A

Response Biomedical Corporation, and Shionogi & Co., Ltd. Announced today the Companies have entered into a Marketing and Supply Agreement to commercialize a rapid quantitative RAMP test in Japan for BNP (B-type natriuretic peptide), a proprietary cardiac marker test to assist in the diagnosis and management of congestive heart failure.

PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/05-15-2006/0004361384&EDATE=)